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Letter to the Editor
TO THE EDITOR: In a recent review of medications and 
impaired driving, the authors concluded that it was difficult 
to determine if impaired driving performance was a result 
of psychotropic medication or the underlying condition.1 
Opioids are associated with sedation and dizziness, and 
there are concerns regarding their impact on driving; how-
ever, data suggest that strong opioids do not necessarily 
impair and may even improve psychomotor, cognitive func-
tioning, and driving ability in patients with chronic noncan-
cer pain.2 Italian law prohibits driving while taking 
psychoactive substances, including opioids, if it causes psy-
chophysical disturbances (Italian Highway Code, Rule 
187); however, roadside assessment is impractical. For 
driving under the influence of alcohol, no evaluation of psy-
chophysical status is required; blood alcohol levels >0.5 g/L 
lead to driving license withdrawal (Italian Highway Code, 
Rule 186).
We report our data from a recent study investigating the 
effects of opioids on psychomotor performance in patients 
with chronic pain and a comparison with volunteers before 
and after alcohol consumption.
After approval from our local ethics committee, we 
compared psychomotor effects in healthy volunteers 
before and after “legal” alcohol exposure (<0.5 g/L) and 
oral fixed-dose prolonged release oxycodone-naloxone 
(OXN), an opioid agonist-antagonist combination effec-
tive for pain treatment with fewer gastrointestinal side 
effects versus other strong opioids, in patients with 
chronic pain. We performed noninvasive simple and com-
plex visual and auditory reflex assessments in 35 volun-
teers (mean age = 36.8 ± 7.9 years) and in 10 patients 
(mean age = 62.2 ± 7.3 years) with severe chronic nonma-
lignant pain (Numerical Rating Scale >6) taking no psy-
chotropic drugs and with preserved mental status (Mini 
Mental Status Examination score >26). Patients were 
assessed at baseline, at 1 week after starting oral OXN 
10 mg twice daily, and after 2 weeks, when the stable 
OXN regimen had achieved good pain relief (Numerical 
Rating Scale ≤3).
After alcohol consumption, 25/35 healthy volunteers 
had blood alcohol <0.5 g/L. Baseline reaction perfor-
mance (Table 1) was worse in patients than in healthy 
volunteers (P < 0.01). In patients, performance did not 
change substantially after 1- and 2-week OXN exposure. 
In volunteers, performance was significantly impaired 
with alcohol <0.5 g/L (P < 0.001). Linear regression anal-
ysis found significant but modest correlations between 
alcohol levels and changes in visual and auditory reflexes 
(P < 0.05 for all), but changes from baseline were similar 
in those with blood alcohol less than or greater than 
0.5 g/L.
The percentage decrease in visual and auditory perfor-
mance after alcohol exposure is consistent with that 
reported by other investigators.3,4 Baseline values in 
patients were significantly worse than in healthy volun-
teers, in accordance with literature suggesting that pain 
negatively affects visual and auditory performance.5 Our 
data support those from previous studies,2 suggesting that, 
unlike healthy volunteers exposed to legal alcohol doses, 
psychomotor functioning, crucial for safe driving, is not 
impaired in patients receiving effective pain relief with 
OXN therapy. Reliable objective noninvasive tools that 
assess visual and auditory reflexes are now available for 
mobile devices for simple roadside evaluation of psycho-
motor and cognitive functioning of drivers with chronic 
pain treated with opioids.
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Table 1. Reaction Times to Simple and Complex Visual and Auditory Reflexes in Healthy Participants at Baseline and After Moderate 
Alcohol Exposure (ie, Causing Blood Alcohol Levels ≤0.49 g/L) and in Patients With Chronic Pain at Baseline and After 1 and 2 Weeks 
of Oral Oxycodone-Naloxone (OXN).
Healthy Volunteers (n = 25) Patients (n = 10)
Reaction Time, ms Baseline
After Alcohol 
Exposure Baseline 1-Week OXN 2-Week OXN
Visual reflex, simple 318.4 ± 65.6 364.5 ± 75.6a 447.7 ± 166.5b 582.8 ± 267.6 457.7 ± 132.0
Auditory reflex, simple 355.7 ± 53.9 394.4 ± 55.1a 846.4 ± 445.8b 692.9 ± 469.7 579.0 ± 248.6
Visual reflex, complex 483.0 ± 44.9 530.9 ± 42.4a 737.3 ± 225.2b 760.2 ± 227.0 659.9 ± 200.8
Auditory reflex, complex 620.1 ± 127.2 684.1 ± 110.7a 1028.0 ± 321.7b 947.6 ± 346.7 901.7 ± 234.7
a<0.001 Versus corresponding baseline value.
b<0.01 Versus corresponding baseline value in healthy volunteers.
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